EU Committee Recommends Approval of Tavneos for Severe, Active AAV

EU Committee Recommends Approval of Tavneos for Severe, Active AAV

311969

EU Committee Recommends Approval of Tavneos for Severe, Active AAV

A committee of the European Medicines Agency has recommended approving Tavneos (avacopan) as an add-on therapy for adults with severe, active microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA), the two most common types of ANCA-associated vasculitis. This recommendation from the Committee for Medicinal Products for Human Use (CHMP) will be reviewed by the European Commission, which is expected to make a final decision early next year. The potential approval will cover all European Union…

You must be logged in to read/download the full post.